Thursday, November 10, 2016 9:06:46 AM
Use of CytoSorb in necrotizing fasciitis and severe septic shock
Dr. Milan Margoc, Dr. Silvia Montag, Doz. Alexander Kulier, Anaesthesiological Intensive Care Unit, Hospital-Elisabethinen Linz
This case study reports on a 53-year-old male patient (previous medical history: arterial hypertension, DM II, COPD, bipolar affective disorder) who was admitted to hospital with a suspected acute scrotal erysipelas.
Case presentation
Admission to the dermatological department with additional presentation to the urological department
One day after admission rapid deterioration of the general condition with presentation at the urological department and immediate referral for surgical procedure (radical inguinal-rectal fasciotomy of Fournier gangrene and necrotizing fasciitis)
Additional need for cardiopulmonary resuscitation whilst still in the operating room and installation of a temporary pacemaker
Postoperative transfer to the intensive care unit in very severe septic shock with multi-organ failure (renal insufficiency, vasoplegia, hemodynamic instability, septic cardiomyopathy), ventilated, under volume therapy, catecholamine-dependent
Highly elevated inflammation parameters (PCT 35.81 ng/ml, leukocytes 37.500/µl, CRP 35.8 mg/dl) and greatly impaired renal function (GFR of 8.8 ml/min)
Antibiotic therapy initially with piperacillin + tazobactam as well as clindamycin, after microbiological findings, plus micafungin
Short-term stabilization under conventional therapy, however, due to his acute renal insufficiency as well as the hemodynamic instability and the increased inflammation markers, the decision was made to initiate CytoSorb as adjunctive therapy together with a CVVHD
Treatment
One treatment with CytoSorb for a total treatment time of 24 hours
CytoSorb was used in conjunction with CRRT (Multifiltrate, Fresenius Medical Care) performed in CVVHD mode
Blood flow rate: 150 ml/min
Anticoagulation: citrate
CytoSorb adsorber position: pre-hemofilter
Measurements
Demand for catecholamines
Renal function (GFR, excretion)
Inflammatory parameters (CRP, PCT, leucocytes)
Results
Hemodynamic stabilization with a significant reduction in catecholamine doses – norepinephrine from initially 0.3-0.91 µg/kg/min to 0.09-0.2 µg/kg/min within the first 24 hours, patient was free from catecholamines 48 hours after completion of CytoSorb treatment
Clear reduction in inflammatory parameters under CytoSorb therapy (CRP 10 mg/l, leukocytes 22.500/µl, PCT 7.39 ng / ml)
Clear improvement in renal function: GFR from 8.8 to 26.6 ml/min within 4 days
Patient Follow-Up
Daily surgical wound care, disinfection, removal of necrotic tissue
Termination of renal replacement therapy 3 days after CytoSorb application with complete recovery of diuresis 13 days later
Weaning and extubation successful 11 days after CytoSorb application
In the days post extubation, the patient presented as clinically stable, was awake, adequately alert, mentally appropriate and was able to tolerate complete oral nutrition
26 days after the use of CytoSorb the patient was discharged to the urological ward with a VAC system
CONCLUSIONS
Treatment with CytoSorb was accompanied by an unexpectedly rapid and significant stabilization in vital functions (renal function, hemodynamics) as well as declining catecholamine doses within a few hours
According to the medical team, the rapid start of treatment with the combination of CytoSorb and CVVHD may have saved the patient‘s life
The installation of the absorber into the CVVH circuit as well as the application of CytoSorb itself was simple and safe
http://cytosorb-therapy.com/the-studies/case-of-the-week/
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM